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Uniparental disomy of chromosome 16
unmasks recessive mutations of
FA2H/SPG35 in 4 families
ABSTRACT
Objective: Identifying an intriguing mechanism for unmasking recessive hereditary spastic
paraplegias.
Method: Herein, we describe 4 novel homozygous FA2H mutations in 4 nonconsanguineous
families detected by whole-exome sequencing or a targeted gene panel analysis providing high
coverage of all known hereditary spastic paraplegia genes.
Results: Segregation analysis revealed in all cases only one parent as a heterozygous mutation
carrier whereas the other parent did not carry FA2H mutations. A macro deletion within FA2H,
which could have caused a hemizygous genotype, was excluded by multiplex ligation-dependent
probe amplification in all cases. Finally, a microsatellite array revealed uniparental disomy (UPD)
in all 4 families leading to homozygous FA2H mutations. UPD was confirmed by microarray
analyses and methylation profiling.
Conclusion: UPD has rarely been described as causative mechanism in neurodegenerative dis-
eases. Of note, we identified this mode of inheritance in 4 families with the rare diagnosis of
spastic paraplegia type 35 (SPG35). Since UPD seems to be a relevant factor in SPG35 and
probably additional autosomal recessive diseases, we recommend segregation analysis espe-
cially in nonconsanguineous homozygous index cases to unravel UPD as mutational mechanism.
This finding may bear major repercussion for genetic counseling, given the markedly reduced risk
of recurrence for affected families. Neurology® 2016;87:186–191
GLOSSARY
DMR 5 differentially methylated region; FA2H 5 fatty acid 2-hydroxylase; HSP 5 hereditary spastic paraplegia; MLPA 5
multiplex ligation-dependent probe amplification; SNP 5 single nucleotide polymorphism; SPG35 5 spastic paraplegia type
35; UPD 5 uniparental disomy.
Hereditary spastic paraplegias (HSPs) are a clinically and genetically heterogeneous group of neuro-
degenerative disorders of the spinal cord affecting mainly the long axons of the corticospinal tract.
Spastic paraplegia type 35 (SPG35) is caused by mutations in the fatty acid 2-hydroxylase (FA2H)
gene located on chromosome 16q23 and is clinically characterized by early-onset spastic tetraparesis,
mental retardation, cerebellar ataxia, and extrapyramidal involvement. FA2H was first described in
2008 as a rare leukodystrophy gene causing spasticity and dystonia.1 It is an NADPH (nicotinamide
adenine dinucleotide phosphate)-dependent monooxygenase essential for maintenance of the neu-
ronal myelin sheath. SPG35 follows an autosomal recessive trait. To date, approximately 19 families
totaling 51 patients have been reported in the literature.
UNIPARENTAL DISOMY Uniparental disomy (UPD) as a concept aroused in the 1980s when analyzing material
from spontaneous abortions, establishing the concept of a random union of a disomic gamete with a gamete
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nullisomic for the homolog. This situation was named
uniparental because both members of such a pair arise
from only one parent.2 UPD is the result of a defective
chromosomal segregation in mitosis or meiosis.3 The
potential of UPD to unmask recessive alleles has been
described for several diseases (see ref. 4 for review). Two
cases have been reported in autosomal recessive spastic
ataxia type Charlevoix-Saguenay.5 In HSP, just one case
with SPG18 was found in a whole-exome approach.6
UPD is a “hot topic” in genetics because of outcome
prediction problems in prenatal diagnosis3 and for the
counseling of families on recurrence risk.
METHODS Patients. Families were seen in the outpatient
clinic for HSP at the University Hospital Tübingen, Germany
(F1, F2, F3), and at the Donostia University Hospital, Spain (F4).
Standard protocol approvals, registrations, and patient
consents. Approval from local ethical committees on human exper-
imentation was received, and written informed consent was obtained
from all patients (or guardians of patients) participating in the study.
Clinical and genetic data are summarized in the table.
Next-generation sequencing. Mutations in the FA2H gene were
uncovered by whole-exome sequencing (F1, F4) or disease-specific
gene panel diagnostics (F2, F3). HSP panel diagnostics screened
.90 known spasticity genes following targeted enrichment by
Agilent in-solution or HaloPlex technology. Genes included in the
panel approach are provided on request. Whole-exome sequencing
was performed using the SureSelect Human All Exon 50 Mb kit
(Agilent, Santa Clara, CA) and HiSeq2000 instruments (Illumina,
San Diego, CA; for technical background, compare ref. 7).
Multiplex ligation-dependent probe amplification assay.
We designed a multiplex ligation-dependent probe amplification
(MLPA) assay targeting all coding exons of the FA2H gene and
the 59 UTR (8 probes in total; available on request) to screen for
FA2H deletions. These target probes were applied in combination
with the SALSA MLPA P300 Human reference probemix (MRC
Holland) according to the manufacturer’s instructions.
Testing for UPD16. The following polymorphic microsatellite
markers on chromosome 16 were analyzed by PCR for index patients
and both parents: D16S3024, D16S3131, D16S511, and D16S413.
PCR amplicons were evaluated by fragment analysis (Beckman Coul-
ter CEQ8000).
Microarray analyses. High-resolution chromosome analysis
(single nucleotide polymorphism [SNP] array analysis) was performed
using the Human CytoScan 750K Array (Affymetrix, Santa Clara,
CA) according to the manufacturer’s instructions. Genotypes and
mendelian errors were detected using the Affymetrix Chromosome
Analysis Software (version 3.0.0.42) and UPDtool.8
Methylation assay. Approximately 1 mg DNA was subjected to
sodium bisulfite treatment using the EZ Methylation-Gold Kit
(ZYMO, Orange, CA). Converted DNA was used as a template
Table Clinical details and variant description of SPG35 cases
Family 1 Family 2 Family 3 Family 4
Ethnicity Serbian German German Spanish
Sex M M F F
Consanguinity 2 2 2 2
Age at examination, y 12 9 6 18
Age at onset, y 3 4 4.5 4
Age at wheelchair use, y 10 7 NA 11
Cognitive deficits Moderate to severe No deficits Mild Mild
Tetraspasticity 1 1 1 1
Limb ataxia UL/LL UL/LL NA (weakness) None UL/LL
Extrapyramidal involvement Rigidity Rigidity 2 Dystonia














MAF EVS 2 2 2 2
MAF ExAC, % 2 2 2 0.00083 (all)
Conservation amino acid NA High High High






PolyPhen-2 (HumDiv) NA 1.000 1.000 0.999
Abbreviations: EVS 5 Exome Variant Server; ExAC 5 Exome Aggregation Consortium; LL 5 lower limb; MAF 5minor allele frequency; NA 5 not applicable;
UL 5 upper limb.
Symbols: 2 5 sign/symptom absent; 1 5 sign/symptom present.
Age at onset 5 beginning of gait disturbance. Variant coordinates refer to GRCh37 and the reference sequence NM_024306.4, respectively. Variant
classification criteria are derived from the ACMG (American College of Medical Genetics and Genomics) criteria.9
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Figure 1 Uniparental disomy in families with spastic paraplegia type 35
The blue/green boxes show the 2 different alleles of the repetitive DNA motif in the tested microsatellite (binned). The
maternal alleles in F1 (A), F2 (C), and F4 (G) or the paternal alleles in F3 (E) cannot be assigned to distinct haplotypes (yellow
boxes). Chromatograms of the index patients and their parents are shown for F1 (B), F2 (D), F3 (F), and F4 (H). The arrow
indicates the position of the base substitution. mut 5 mutation; wt 5 wild-type.
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for PCR, with the amplicons cloned into pGEM-T Easy Vector
(Promega), transfected into JM109 and individual colonies
sequencing using standard T7 sequence primer.
Pyrosequencing was performed to quantitate methylation of
each amplicon. Standard primers were used with the exception
that the reverse primer was biotin-labeled. PCR products were
sequenced using a PyroMark Q96 MD machine.
RESULTS Mutation analysis. Three novel missense
variants and one nonsense variant (compare the table)
were identified, which were not listed with significant
frequencies in public databases (EVS [Exome Variant
Server], ExAC [Exome Aggregation Consortium], and
dbSNP). The missense variants affect highly conserved
amino acids and are predicted to be damaging, e.g., by
PolyPhen-2. All variants appeared to be homozygous.
Because of their rarity, the matching clinical phenotype,
their homozygous appearance, conservation of affected
amino acids, in silico predictions for missense variants,
and predicted loss-of-function for the nonsense
mutation, these variants were classified as likely
pathogenic (class 4, derived from ACMG [American
College of Medical Genetics and Genomics] criteria9).
Figure 2 In-depth characterization of UPD16 in families with spastic paraplegia type 35
(A) UPD confirmed bymicroarray analysis. The CN state indicates the normal DNACN for all index patients. A lack of heterozygosity at the FA2H locus is shown
in the allele difference plots. Heterozygous alleles in index F3 refer to the heterodisomy, homozygous alleles to the segmental isodisomy. (B) Confirmation of
UPD16 by ZNF597-imprinted DMR methylation pyrosequencing. Strand-specific methylation profiles for the ZNF597 DMRs as determined by cloning and
direct sequencing. Each circle represents a singleCpGdinucleotide on aDNA strand (results formultipleDNA strands are depicted as rows), filled circles indicate
amethylated cytosine, and open circles an unmethylated cytosine. Note that the sample used for the PCR of the paternally methylated region was heterozygous
for a polymorphism (rs2270497) that allowed for allelic origin of methylation to be ascertained. The boxes indicate the CpG sites quantified by pyrosequencing.
(C) The average methylation as determined by pyrosequencing in control samples for both DMRs is consistent with one methylated and unmethylated allele.
pUPD16 cases (blue data points) and mUPD16 (red data points) showing reciprocal methylation profiles consistent with parental origin. The control box plots
represent the interquartile range for control samples andwhiskers span from5th to95th percentile. CN5 copy number; DMR5 differentially methylated region;
UPD 5 uniparental disomy.
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Segregation testing and identification of UPD in 4 families.
Mutations identified through next-generation sequencing
were confirmed by Sanger sequencing. In all families,
neither consanguinity nor a founder effect were
supported by family history. When sequencing the
parents, surprisingly, the respective mutation was
found either only in the fathers while the mothers
were wild-type (F1, F2, and F4) or the mother was
identified as a heterozygous carrier with the father
being wild-type (F3) (figure 1). MLPA excluded
genomic deletions in all 4 index patients. To trace
segregation of the maternal and paternal alleles,
we then genotyped 4 polymorphic microsatellite
markers spanning regions of 198–258 base pairs on
chromosome 16 surrounding the FA2H gene. In F1,
2 identical alleles of the FA2H gene, both carrying
the W176* mutation, were inherited from the father
and none of the maternal FA2H alleles was passed on
to the index case. Likewise, in F2 and F4, 2 identical
FA2H alleles were paternally inherited, causing
homozygosity for the mutations Pro44Gln and
Lys262Thr, respectively, in the affected offspring. In
F3, the affected child presented with a maternal
heterodisomy and additionally a segmental maternal
isodisomy (marker D16S511, approximately 6 Mb
downstream of the FA2H gene). These findings
confirm a paternal isodisomic UPD of chromosome
16 in F1, F2, and F4 as well as a maternal heterodisomic
UPD with a segmental isodisomic UPD16 in F3 (see
figure 1).
In-depth analysis of UPD16 in SPG35 cases. For a more
accurate evaluation of the UPDs, we performed SNP
array analyses of all patients and their parents. All
patients showed homozygous genotypes at the FA2H
gene locus. In F1, F2, and F4, homozygosity was spread
over the entire chromosome 16. The index patient of F3
showed a homozygous stretch of approximately 10 Mb
(72,301,683–82,494,755). An example of the genotyp-
ing data is shown in figure 2. The mendelian error check
from the Affymetrix Chromosome Analysis Software
identified elevated maternal error rates on chromosome
16, indicating a paternal UPD16 in families F1, F2,
and F4. The index patient of F3 showed an increased
paternal error rate, indicating a maternal UPD. The
UPDtool8 confirmed paternal isodisomy of chromosome
16 for F1, F2, and F4 and maternal partial heterodisomy
and isodisomy of chromosome 16 for F3.
To confirm the UPDs, we performed DNAmethyl-
ation profiling of the 2 reciprocally imprinted differen-
tially methylated regions (DMRs) associated with the
ZNF597 gene at 16q13.3. Bisulfite PCR products
incorporated 31 CpG dinucleotides in the amplicon
targeting the paternally methylated DMR and 10 CpGs
in the maternally methylated DMR (figure 2B). Sub-
sequent pyrosequencing analysis was limited to 4 CpG
dinucleotides with the arithmetic mean used as a repre-
sentative measure of methylation for each index case,
parents, and 14 controls. All probands were clearly dis-
tinguishable from controls with the pUPD16 cases
being relatively hypermethylated at the paternally meth-
ylated DMR and unmethylated at the maternal DMR
with the opposite profile observed for proband F3 with
mUPD16 (figure 2C).
Clinical findings. All 4 children presented with a com-
plicated form of HSP with tetraspasticity and addi-
tional symptoms including limb ataxia (3/4), mild
cognitive deficits (3/4), and extrapyramidal involve-
ment (3/4). See the table for clinical details.
DISCUSSION UPD as cause for autosomal recessive
diseases and especially HSP appears to be more common
than previously thought. When looking from a genome-
wide perspective,10 an estimated rate of segmental UPD
is thought to be at 0.578% based on a UPD screening,
or 0.026% based on autosomal chromosome pairs
investigated in the general population. These data
imply the possibility of hidden segmental UPD in
the general population.10 Here, we present 4 cases
of SPG35 caused by UPD16.
The high number of UPD16 cases currently identi-
fied as cause of SPG35 is surprising. However, trisomy
16 is the most common trisomy in human pregnan-
cies.3 According to a recent review,3 supernumerary
chromosome 16 is always of maternal origin; therefore,
a maternal UPD16 is frequently observed as a result of
trisomic rescue. However, paternal UPD16 has also
been described. In the absence of a recessive mutation,
the outcome was reported to be normal.11
The clinical picture of all index patients is in accor-
dance with the phenotypic spectrum previously described
for patients with compound heterozygous or homozy-
gous FA2H mutation. SPG35 usually begins in early
childhood after a normal early development. The initial
symptom in the vast majority of SPG35 cases is spastic
gait followed by multisystemic affection in accordance
with the patients presented here. There is ongoing debate
about whether UPD16 is associated with consistent
imprinting phenotypes (mUPD16: intrauterine growth
restriction with anal atresia12; pUPD16: alveolar capillary
dysplasia with misalignment of pulmonary veins13).
Since our index cases do not represent such features,
it is unlikely that UPD16 directly contributes to these
presentations.
UPD seems to be a rather frequent genetic mecha-
nism for homozygous mutations in FA2H in noncon-
sanguineous families. DNA samples of the parents
should be collected more often to perform segrega-
tion analysis because the detection of UPD is of
major relevance for the risk of recurrence and
genetic counseling.
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